From June 1 to 3, China Pharmaceutical University hosted the Sino-German International Symposium on Intelligent Pharmacy and the 2025 Annual Meeting of the Global Center for Gender Research in Biology and Medicine in Nanjing. The theme of the conference was “Focusing on the Cutting Edge of International Pharmaceutical Research, Discussing the Future of Global Intelligent Pharmacy.” The conference was co-chaired by Hao Haiping, president of China Pharmaceutical University, and Frank Kirchhoff, director of the Center for Gender Research in Biology and Medicine at Saarland University in Germany.
To promote the deep integration of intelligent technology and pharmaceutical research, and to explore broader applications for intelligent pharmacy, this symposium brings together top scholars and industry experts from China and Germany. It aims to delve into cutting-edge technologies, research findings, and applications of intelligent pharmacy in global health management, providing a high-level academic exchange platform for innovative drug development and fostering interdisciplinary collaboration.
Hao Haiping introduced that the Sino-German Drug Research and Development Cooperation Symposium focused on cross-border collaboration and “AI+pharmacy” innovation. Both sides emphasized that new drug research and development requires interdisciplinary cooperation to address global health threats such as antibiotic resistance. The Global Pharmacy Development Alliance was launched in 2018 and is committed to cross-border talent cultivation and cooperation in the research and development of drugs for major diseases.
Frank Kirhoff said that the strengths of both Germany and China will not only be reflected in joint research projects, but will also influence the teaching, education, and training of students and early-career researchers, jointly promoting more efficient and innovative pharmaceutical research and development.
The conference also invited several renowned professors from the Medical School and School of Pharmacy at Saarland University in Germany, as well as the director and chief scientist team from the Helmholtz Institute for Pharmaceutical Research. Experts in attendance engaged in in-depth exchanges and discussions on topics such as multi-omics data-driven original target discovery, advances in intelligent synthetic biology technology, genome-guided biopharmaceutical synthesis, and AI-enabled drug screening.
